72 Tremaroli, V
Weight Loss: Comparable to Bariatric Outcomes Tirzepatide has shown an unprecedented effect on body weight among antidiabetic drugs: Average weight loss of 10.515 kg (2333 lbs) in type 2 diabetes patients Even greater results (up to 22.5% body weight reduction) in non-diabetic individuals with obesity, per the SURMOUNT-1 trial This places Tirzepatide in competition with dedicated weight-loss medications and even some bariatric procedures, making it a dual-action solution for metabolic disease
Application frequency for GHK-CU Topical Cream varies depending on individual skin type and anti-aging goals
Lang E, Zelenak C, Eberhard M, Bissinger R, Rotte A, Ghashghaeinia M, et al
Staying proactive about other weight management strategies, such as exercising, eating a balanced diet, and working with a team of weight loss professionals, can help minimize weight regain after stopping semaglutide.